Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.03.2024 | Case report

Tildrakizumab

Various toxicities

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Berenguer-Ruiz S, et al. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. Journal of the European Academy of Dermatology and Venereology 37 : 2517-2525, No. 12, Dec 2023. Available from: URL: https://dx.doi.org/10.1111/jdv.19468 Berenguer-Ruiz S, et al. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. Journal of the European Academy of Dermatology and Venereology 37 : 2517-2525, No. 12, Dec 2023. Available from: URL: https://​dx.​doi.​org/​10.​1111/​jdv.​19468
Metadaten
Titel
Tildrakizumab
Various toxicities
Publikationsdatum
01.03.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-54665-9

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Bevacizumab

Case report

Methotrexate